Zydus Lifesciences on Monday said it has received approval from US health regulator USFDA to market a generic antifungal medication to treat dandruff, fungal infections, and other skin conditions.
The company has received final approval from the US Food and Drug Administration to manufacture Ketoconazole Shampoo, 2 pc, it said in a statement.
Ketoconazole shampoo is an antifungal medication used to treat dandruff, fungal infections, and other skin conditions.
The product will be produced at the Zydus Group's topical manufacturing site at Changodar, Ahmedabad.
ADVERTISEMENT
As per IQVIA MAT January 2025 data, Ketoconazole shampoo had annual sales of $68.89 mn in the US.
Shares of Zydus Lifesciences were trading 0.22% up at Rs 903.10 apiece on BSE.
Add us to your Preferences
Set as your preferred source on Google
ADVERTISEMENT
RECOMMENDED FOR YOU
Phoenix Mills' Rs 5,450-Crore Stake Buy In Island Star Mall Developers Gets CCI Nod
Aug 19, 2025
Hindustan Zinc Gets Board Nod For 10 MTPA Tailings Reprocessing Plant Worth Rs 3,823 Crore
Aug 18, 2025
Indian Company's Cookware Products Likely To Cause Lead Poisoning, USFDA Warns
Aug 18, 2025
Dr Reddy's Gets Form 483 With Seven Observations From USFDA After Inspection At Andhra Unit
Jul 18, 2025
POPULAR
1
Dream11, Zupee, MPL Prepare To Shut Real-Money Gaming Business After Centre's Stringent Law
2
Israel's Capture Of Gaza: What Has Gone On So Far, What IDF Plans To Do Next — 10 Points
3
Titagarh Rail Gets Rs 467-Crore Order From Garden Reach Shipbuilders
4
'Making India Hub For Gaming': PM Modi Hails Passage Of Online Gaming Bill
5